8-K: OSR Health Amends License Agreement, Shifts Equity Option to Convertible Notes

OSR Health, Inc. has amended its license agreement with BCM Europe AG, converting a $15 million equity option into a convertible note structure due to Nasdaq delisting concerns.

Summary

• OSR Health, Inc. (OSRH) and its subsidiary Vaximm AG have amended their Global Exclusive License Agreement for VXM01 with BCM Europe AG (BCME).
• The amendment addresses the Nasdaq Staff's delisting determination issued on August 19, 2026.
• OSR Health can now elect to convert all or part of its existing $15 million Equity Option into a Convertible Note Option.
• Under the Convertible Note Option, OSRH will issue convertible notes up to $15 million, which BCME will purchase at par.
• These notes will be issued in four tranches of $3.75 million each, with fixed conversion prices of approximately $2.00, $3.00, $4.00, and $5.00 per share.
• If the Minimum Price (as defined by Nasdaq Rule 5635) on the purchase commitment date exceeds a tranche's conversion price, the conversion price will be set at the Minimum Price.
• BCME must provide a purchaser's binding commitment before OSRH issues the Note Election Notice.
• The closing for the convertible note purchase must occur within 20 business days of the notice, with a 10-day grace period; otherwise, the election is withdrawn, and the original Equity Option is reinstated.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the shift from a direct equity option to a convertible note structure, which introduces conversion price uncertainty and potential dilution.

Positives

• Provides an alternative settlement mechanism for the $15 million equity option, offering flexibility in light of Nasdaq delisting concerns.
• The convertible note structure offers fixed conversion prices (subject to Nasdaq Minimum Price) which provides some predictability compared to a direct equity sale.
• BCME is responsible for identifying a purchaser and securing a binding commitment, which could expedite the process.
• The amendment includes a provision for the reinstatement of the original equity option if the convertible note closing does not occur within the specified timeframe.

Negatives

• The shift from a direct equity option to convertible notes introduces potential future dilution for existing shareholders.
• The conversion prices are set at a premium to the current market, but the Nasdaq Minimum Price clause could lead to higher effective conversion prices if the stock price recovers significantly.
• The delisting determination by Nasdaq creates uncertainty around the company's stock trading status and future liquidity.
• The structure implies that OSRH may not be able to meet the original equity purchase terms, necessitating this alternative.

Risks

• Potential delisting from The Nasdaq Stock Market could significantly impact the company's ability to raise capital and its stock liquidity.
• The conversion of notes into common stock at prices ranging from $2.00 to $5.00 per share could lead to substantial dilution for existing shareholders.
• If the company's stock price falls below the conversion prices, the notes may not be converted, potentially leaving OSRH with unfulfilled financing obligations.
• The failure of the convertible note purchase to close within the stipulated timeframe would revert the situation to the original equity option, which may still be problematic given the delisting concerns.

Future Outlook

The amendment provides OSRH with an alternative settlement method for a significant financial obligation, which is crucial given the Nasdaq delisting determination. The success of this alternative hinges on BCME securing a purchaser and the closing proceeding as planned.

Management Comments

• The Parties acknowledge that the delisting determination issued by the Nasdaq Staff on August 19, 2026 is a material subsequent development affecting settlement of the Equity Option.
• The rights in this Section 6.10 apply whether or not that determination is later stayed, extended, conditionally granted or followed by relisting.

Industry Context

StockSavvy.ai notes that companies facing potential delisting often explore alternative financing or settlement mechanisms. The shift to convertible notes is a common strategy, but it introduces dilution risk and depends heavily on the investor's confidence in the company's ability to eventually relist or maintain operations.

Legal Proceedings

• The Nasdaq Staff issued a delisting determination on August 19, 2026, which is a significant regulatory event impacting the company's stock.

Stakeholder Impact

• Shareholders: Potential dilution from the conversion of convertible notes into common stock.
• Creditors: The company is restructuring a financial obligation, which could impact its debt profile.
• Management: Faces the challenge of navigating the delisting process and securing financing.

Next Steps

• OSR Health must issue a written notice to BCME to elect the Convertible Note Option.
• BCME must deliver the purchaser's binding commitment to purchase the Convertible Notes.
• Closing of the convertible note purchase is expected to occur no fewer than twenty (20) Business Days after the Note Election Notice.
• If the closing does not occur within ten (10) Business Days after the scheduled closing date, the Note Election Notice will be deemed withdrawn, and the Equity Option will be reinstated.

Key Dates

Recommendation

The amendment provides a necessary alternative to a potentially problematic equity sale, but the underlying issue of Nasdaq delisting and the inherent dilution from convertible notes warrant caution. A 'hold' recommendation reflects the uncertainty and the need for further clarity on the company's path forward.

Keywords

Convertible Notes, License Agreement Amendment, Equity Option, VXM01, Vaximm AG, BCM Europe AG, Nasdaq Delisting, Capital Raise